BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23288633)

  • 21. Apoptosis and colorectal cancer: implications for therapy.
    Yang SY; Sales KM; Fuller B; Seifalian AM; Winslet MC
    Trends Mol Med; 2009 May; 15(5):225-33. PubMed ID: 19362056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular therapy of colorectal cancer: progress and future directions.
    Weng W; Feng J; Qin H; Ma Y
    Int J Cancer; 2015 Feb; 136(3):493-502. PubMed ID: 24420815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising targets and drugs in development for colorectal cancer.
    Thompson C; Leong S; Messersmith W
    Semin Oncol; 2011 Aug; 38(4):588-97. PubMed ID: 21810518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
    Zhang J; Roberts TM; Shivdasani RA
    Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer.
    Jain VK; Hawkes EA; Cunningham D
    Clin Colorectal Cancer; 2011 Dec; 10(4):245-57. PubMed ID: 21729675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted nanoparticles for colorectal cancer.
    Cisterna BA; Kamaly N; Choi WI; Tavakkoli A; Farokhzad OC; Vilos C
    Nanomedicine (Lond); 2016 Sep; 11(18):2443-56. PubMed ID: 27529192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
    Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
    Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ApoG2 inhibits the antiapoptotic protein, Mcl‑1, and induces mitochondria‑dependent apoptosis in human colorectal cancer cells.
    Li T; Yuan G; Zhang L; Ye L; Li S; Fan Y; Sun J
    Mol Med Rep; 2015 Nov; 12(5):6976-84. PubMed ID: 26352605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel targets for anticancer treatment development in colorectal cancer.
    Macarulla T; Ramos FJ; Capdevila J; Saura C; Tabernero J
    Clin Colorectal Cancer; 2006 Nov; 6(4):265-72. PubMed ID: 17241511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel agents in the treatment of metastatic colorectal cancer.
    Leong S; Messersmith WA; Tan AC; Eckhardt SG
    Cancer J; 2010; 16(3):273-82. PubMed ID: 20526106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging drugs in refractory colorectal cancer.
    Nobili S; Galletta A; Brugia M; Tassi R; Petreni P; Landini I; Mini E
    Future Med Chem; 2015 Aug; 7(12):1491-501. PubMed ID: 26293581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Search for novel target molecules for the effective treatment or prevention of colorectal cancer.
    Tsujii M
    Digestion; 2012; 85(2):99-102. PubMed ID: 22269287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel drug discovery opportunities for colorectal cancer.
    Curtin JC
    Expert Opin Drug Discov; 2013 Sep; 8(9):1153-64. PubMed ID: 23768167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combinational treatment with microRNA‑133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR.
    Zhou J; Lv L; Lin C; Hu G; Guo Y; Wu M; Tian B; Li X
    Mol Med Rep; 2015 Oct; 12(4):5407-14. PubMed ID: 26151111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The promise of mTOR inhibitors in the treatment of colorectal cancer.
    Kim DD; Eng C
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1775-88. PubMed ID: 22978346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.
    Clark JW
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-19-S18-24. PubMed ID: 9420017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetics of colorectal cancer.
    Hisamuddin IM; Yang VW
    MedGenMed; 2004 Aug; 6(3):13. PubMed ID: 15520636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epithelial-mesenchymal transition‑associated microRNAs in colorectal cancer and drug-targeted therapies (Review).
    Jin D; Fang Y; Li Z; Chen Z; Xiang J
    Oncol Rep; 2015 Feb; 33(2):515-25. PubMed ID: 25435189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
    Serrano C; Markman B; Tabernero J
    Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.